Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6944593 | 1.00 | POLB (0.46) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL2177134 | 1.00 | POLB (0.46) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL7347136 | 1.00 | POLB (0.46) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL13387830 | 0.92 | POLB (0.45) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL12234850 | 0.92 | POLB (0.48) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL13379347 | 0.91 | PDK1 (0.47) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL23364628 | 0.90 | POLB (0.46) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL13388734 | 0.90 | POLB (0.44) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL17124819 | 0.90 | POLB (0.46) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL6936752 | 0.89 | POLB (0.50) | POLBPDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403805-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403805-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403805-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150274711-A1 | Antiviral Compounds | HOFFMANN-LA ROCHE INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150274711-A1 | Antiviral Compounds | HOFFMANN-LA ROCHE INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150274711-A1 | Antiviral Compounds | HOFFMANN-LA ROCHE INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150218146-A1 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | ABBVIE DEUTSCHLAND (DE) | 2015-08-06 | — | — | US | disclosed |
| US-20150218146-A1 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | ABBVIE DEUTSCHLAND (DE) | 2015-08-06 | — | — | US | disclosed |
| US-9090559-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090559-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20090240045-A1 | Organic Compounds | NOVARTIS AG | 2009-09-24 | — | — | US | disclosed |
| US-7452908-B2 | Amide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-11-18 | — | — | US | disclosed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| EP-1861412-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | Novartis AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| WO-2007063123-A1 | SUBSTITUTED OXINDOL-DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2007-06-07 | — | — | WO | disclosed |
| WO-2006097260-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| US-6809108-B1 | SELECTIVE MUSCARINIC M3 RECEPTOR ANTAGONTS; REDUCED SIDE EFFECTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-10-26 | — | — | US | disclosed |
| US-20040204369-A1 | Novel amide derivatives | MSD K.K. (JP) | 2004-10-14 | — | — | US | disclosed |
| EP-1213281-B1 | NOVEL AMIDE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-02-18 | — | — | EP | disclosed |
| EP-1213281-A1 | NOVEL AMIDE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274711-A1 | Antiviral Compounds | HAVCR2, EIF2AK2, MAVS | POLB 269/4885PDK1 2774/4885PDK2 2382/4885 |
| US-20040204369-A1 | Novel amide derivatives | CHRM3, CHRM1, CHRM2 | POLB 3871/4885PDK1 4183/4885PDK2 3492/4885 |
| US-20080242683-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | POLB 1773/4885PDK1 1211/4885PDK2 1282/4885 |
| US-20150218146-A1 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | AVPR2, AVPR1B, AVPR1A | POLB 4776/4885PDK1 1460/4885PDK2 568/4885 |
| US-20090240045-A1 | Organic Compounds | CYP3A43, CYP3A4, SLCO1B3 | POLB 1340/4885PDK1 648/4885PDK2 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.